| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8668499 | Journal of Clinical Lipidology | 2018 | 12 Pages |
Abstract
High-dose atorvastatin is more effective in achieving non-HDL-C therapeutic goals and in modifying LDL-related parameters. Recommended apoB treatment targets may require revision. Despite the increase in adiponectin and the decrease in serum amyloid A, HDL showed no change in functionality.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Handrean MSc, MD, FRCP, Yifen PhD, Safwaan MRCP, Tarza PhD, Jan H. MRCP, Jonathan D. BSc, PhD, MRCP, See MD, Matthew PhD, Michael MRCPath, Naveed MD, FRCP, J.Martin MD, PhD, FRCP, Paul N. MD, FRCP, FRCPath, FAHA, FMedSci, Martin K. MD, FRCP,